Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: A preliminary report

Urologia Internationalis

Volumn 85, Issue 3, 2010, Pages 334-340

  Zhu, Yao ^a,b   Li, Hui ^c   Yao, Xu Dong ^a,b   Zhang, Shi Lin ^a,b   Zhang, Hai Liang ^a,b   Shi, Guo Hai ^a,b   Yang, Li Feng ^a,b   Yang, Zhong Yi ^a,b   Wang, Chao Fu ^a,b   Ye, Ding Wei ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Metastasis; Penile cancer; Sorafenib; Squamous cell carcinoma; Sunitinib

Indexed keywords

CD34 ANTIGEN; CETUXIMAB; ERLOTINIB; KI 67 ANTIGEN; SORAFENIB; SUNITINIB; TUMOR ANTIGEN;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LABELING INDEX; MICROVASCULATURE; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; PAIN; PENIS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PENILE NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78049460245     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315432     Document Type: Article

References (19)

1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P: Cancer Incidence in Five Continents. IARC Scientific Publications No 160. Lyon, IARC, 2007, vol 9.
2. Goodman MT, Hernandez BY, Shvetsov YB: Demographic and pathologic differences in the incidence of invasive penile cancer in the United States, 1995-2003. Cancer Epidemiol Biomarkers Prev 2007; 16: 1833-1839.
3. Hegarty PK, Kayes O, Freeman A, Christopher N, Ralph DJ, Minhas S: A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int 2006; 98: 526-531. (Pubitemid 44185869)
4. Protzel C, Hakenberg OW: Chemotherapy in patients with penile carcinoma. Urol Int 2009; 82: 1-7.
5. Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED: Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: A Southwest Oncology Group study. J Urol 1999; 161: 1823-1825. (Pubitemid 29420741)
6. Wang LX, Agulnik M: Promising newer molecular- targeted therapies in head and neck cancer. Drugs 2008; 68: 1609-1619.
7. Blick SK, Scott LJ: Cetuximab: A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67: 2585-2607. (Pubitemid 350159168)
8. Pagliaro LC, Osai W, Tamboli P, Vakar-Lopez F, Pettaway CA: Epidermal growth factor receptor expression in and targeted therapy for metastatic squamous cell carcinoma of the penis (abstract). J Clin Oncol 2007; 25: 14045.
9. Obermair A, Kohlberger P, Bancher-Todesca D, Tempfer C, Sliutz G, Leodolter S, Reinthaller A, Kainz C, Breitenecker G, Gitsch G: Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol Oncol 1996; 63: 204-209. (Pubitemid 26398600)
10. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337. (Pubitemid 36109749)
11. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109. (Pubitemid 39331023)
12. Uemura H, Shinohara N, Naito S, Akaza H: A phase II study of the efficacy and safety of sunitinib in treatment-naïve and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC) (abstract). J Clin Oncol 2008; 26: 16108.
13. Graafland NM, Leijte JA, Valdes Olmos RA, Hoefnagel CA, Teertstra HJ, Horenblas S: Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Eur Urol 2009; 56: 339-345.
14. Zhu Y, Zhou XY, Yao XD, Dai B, Ye DW: The prognostic significance of p53, Ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery. BJU Int 2007; 100: 204-208. (Pubitemid 46878560)
15. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/ or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum- based therapy. J Clin Oncol 2007; 25: 2171-2177. (Pubitemid 46954639)
16. Di Silverio F, Sciarra A, Parente U, Andrea A, Von Heland M, Panebianco V, Passariello R: Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008; 80: 451-453. (Pubitemid 351915038)
17. Bevan-Thomas R, Slaton JW, Pettaway CA: Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: The M.D. Anderson Cancer Center Experience. J Urol 2002; 167: 1638-1642. (Pubitemid 34240689)
18. Link RE, Soltes GD, Coburn M: Treatment of acute inguinal hemorrhage from metastatic penile carcinoma using an endovascular stent graft. J Urol 2004; 172: 1878-1879. (Pubitemid 39363078)
19. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191. (Pubitemid 41095154)